Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 14, 2014, Pages 5189-5194

  Lu, Jinghua ^a   Yu, Yadong ^b   Zhu, Iowis ^a   Cheng, Yifan ^b   Sun, Peter D ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HDL binding site; Heparan sulfate binding site

Indexed keywords

AMYLOID; GLYCOSAMINOGLYCAN; HIGH DENSITY LIPOPROTEIN; SERUM AMYLOID A;

AMYLOIDOSIS; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DISSOCIATION; HUMAN; HUMAN TISSUE; HYDROGEN BOND; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

HDL BINDING SITE; HEPARAN SULFATE BINDING SITE;

AMINO ACID SEQUENCE; AMYLOIDOSIS; BINDING SITES; GLYCOSAMINOGLYCANS; HUMANS; INFLAMMATION; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; PROTEIN FOLDING; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; SERUM AMYLOID A PROTEIN;

EID: 84898028057     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1322357111     Document Type: Article

References (38)

1. Pettersson T, Konttinen YT, Maury CP (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9(12):2117-2128.
2. Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME (2010) Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 38(2-3):97-106.
3. Tuglular S, et al. (2002) A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 17(11):2003-2005.
4. Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15(4): 262-268.
5. Cocco E, et al. (2009) Serum amyloid A (SAA): A novel biomarker for uterine serous papillary cancer. Br J Cancer 101(2):335-341.
6. Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA (1983) Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 42(6):665-667.
7. Zahedi K, et al. (1991) Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and-resistant mouse strains. Inflammation 15(1): 1-14.
8. Findeisen P, et al. (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 27(13):2199-2208.
9. Uhlar CM, Whitehead AS (1999) Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 265(2):501-523.
10. Nelson R, Eisenberg D (2006) Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16(2):260-265.
11. Dember LM, et al.; Eprodisate for AA Amyloidosis Trial Group (2007) Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 356(23):2349-2360.
12. Röcken C, et al. (2005) Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: Cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 64(6):808-815.
13. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD (1994) Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1226(3):323-329.
14. Chou KC, Maggiora GM, Némethy G, Scheraga HA (1988) Energetics of the structure of the four-alpha-helix bundle in proteins. Proc Natl Acad Sci USA 85(12):4295-4299.
15. Sun PD, Foster CE, Boyington JC (2004) Overview of protein structural and functional folds. Curr Protoc Protein Sci 35:17.1.1-17.1.189.
16. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA (1991) Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252(5014):1817-1822.
17. Wang L, Lashuel HA, Walz T, ColonW (2002) Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA 99(25):15947-15952.
18. Wang Y, et al. (2011) Serum amyloid A 2.2 refolds into a octameric oligomer that slowly converts to a more stable hexamer. Biochem Biophys Res Commun 407(4): 725-729.
19. Wang L, Lashuel HA, Colón W (2005) From hexamer to amyloid: Marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature. Amyloid 12(3):139-148.
20. Srinivasan S, et al. (2013) Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2. J Biol Chem 288(4):2744-2755.
21. Snow AD, Kisilevsky R, Stephens C, Anastassiades T (1987) Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation. Qualitative and quantitative analysis. Lab Invest 56(6):665-675.
22. Snow AD, Bramson R, Mar H, Wight TN, Kisilevsky R (1991) A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J Histochem Cytochem 39(10):1321-1330.
23. Ancsin JB, Kisilevsky R (1999) The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274(11):7172-7181.
24. Elimova E, Kisilevsky R, Ancsin JB (2009) Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: Evidence for a proamyloidogenic histidine molecular switch. FASEB J 23(10):3436-3448.
25. Noborn F, Ancsin JB, Ubhayasekera W, Kisilevsky R, Li JP (2012) Heparan sulfate dissociates serum amyloid A (SAA) from acute-phase high-density lipoprotein, promoting SAA aggregation. J Biol Chem 287(30):25669-25677.
26. Patel H, Bramall J, Waters H, De Beer MC, Woo P (1996) Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by sitedirected mutagenesis. Biochem J 318(Pt 3):1041-1049.
27. Wang L, Colón W (2004) The interaction between apolipoprotein serum amyloid A and high-density lipoprotein. Biochem Biophys Res Commun 317(1):157-161.
28. Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583-596.
29. LeVine H III (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309:274-284.
30. Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD (1995) In vitro degradation of serum amyloid A by cathepsin D and other acid proteases: Possible protection against amyloid fibril formation. Scand J Immunol 41(6):570-574.
31. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L (2004) Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat Biotechnol 22(10):1302-1306.
32. Thompson MJ, et al. (2006) The 3D profile method for identifying fibril-forming segments of proteins. Proc Natl Acad Sci USA 103(11):4074-4078.
33. Lashuel HA, et al. (2003) Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 332(4): 795-808.
34. Dong LM, et al. (1996) Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol 3(8):718-722.
35. Chen J, Li Q, Wang J (2011) Topology of human apolipoprotein E3 uniquely regulates its diverse biological functions. Proc Natl Acad Sci USA 108(36):14813-14818.
36. Murshudov GN, et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67(Pt 4):355-367.
37. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58(Pt 11):1948-1954.
38. Brown PH, Schuck P (2008) A new adaptive grid-size algorithm for the simulation of sedimentation velocity profiles in analytical ultracentrifugation. Comput Phys Commun 178(2):105-120.